TG Therapeutics, Inc. (TGTX)
56.05
+1.78
(+3.28%)
USD |
NASDAQ |
Aug 24, 16:00
56.45
+0.40
(+0.71%)
After-Hours: 20:00
TG Therapeutics Net Income (Quarterly) : 7.781M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 7.781M |
| March 31, 2026 | 19.78M |
| December 31, 2025 | 23.04M |
| September 30, 2025 | 390.90M |
| June 30, 2025 | 28.19M |
| March 31, 2025 | 5.06M |
| December 31, 2024 | 23.33M |
| September 30, 2024 | 3.88M |
| June 30, 2024 | 6.879M |
| March 31, 2024 | -10.71M |
| December 31, 2023 | -14.42M |
| September 30, 2023 | 113.93M |
| June 30, 2023 | -47.61M |
| March 31, 2023 | -39.23M |
| December 31, 2022 | -52.99M |
| September 30, 2022 | -35.82M |
| June 30, 2022 | -40.51M |
| March 31, 2022 | -69.01M |
| December 31, 2021 | -93.34M |
| September 30, 2021 | -85.64M |
| June 30, 2021 | -78.50M |
| March 31, 2021 | -90.63M |
| December 31, 2020 | -88.22M |
| September 30, 2020 | -87.16M |
| June 30, 2020 | -52.88M |
| Date | Value |
|---|---|
| March 31, 2020 | -51.12M |
| December 31, 2019 | -39.57M |
| September 30, 2019 | -61.93M |
| June 30, 2019 | -36.21M |
| March 31, 2019 | -35.16M |
| December 31, 2018 | -53.86M |
| September 30, 2018 | -33.95M |
| June 30, 2018 | -44.14M |
| March 31, 2018 | -41.53M |
| December 31, 2017 | -30.86M |
| September 30, 2017 | -31.54M |
| June 30, 2017 | -28.35M |
| March 31, 2017 | -27.73M |
| December 31, 2016 | -23.67M |
| September 30, 2016 | -24.83M |
| June 30, 2016 | -15.90M |
| March 31, 2016 | -13.85M |
| December 31, 2015 | -17.61M |
| September 30, 2015 | -13.66M |
| June 30, 2015 | -17.10M |
| March 31, 2015 | -14.58M |
| December 31, 2014 | -18.80M |
| September 30, 2014 | -17.45M |
| June 30, 2014 | -11.99M |
| March 31, 2014 | -7.547M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Krystal Biotech, Inc. | 54.77M |
| MAIA Biotechnology, Inc. | -7.944M |
| Vericel Corp. | 2.206M |
| Incyte Corp. | 585.60M |
| Regeneron Pharmaceuticals, Inc. | 1.297B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 240.34M |
| Total Expenses (Quarterly) | 232.55M |
| EPS Diluted (Quarterly) | 0.0495 |
| Enterprise Value | 8.510B |
| Gross Profit Margin (Quarterly) | 82.86% |
| Profit Margin (Quarterly) | 3.24% |
| Earnings Yield | 4.90% |
| Operating Earnings Yield | 1.53% |
| Normalized Earnings Yield | 4.992 |